AbbVie's schizophrenia drug misses main goals of two trials-March 2024-www.financetom.com

AbbVie's schizophrenia drug misses main goals of two trials

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

AbbVie's schizophrenia drug misses main goals of two trials

Nov 11, 2024 6:19 AM

Nov 11 (Reuters) - AbbVie ( ABBV ) said on Monday its

experimental schizophrenia drug failed to meet the main goal of

two mid-stage trials.

(Reporting by Puyaan Singh in Bengaluru; Editing by Shinjini

Ganguli)

Previous page： Sherpa climbs Mount Everest for record 23rd time Next page： Jet Airways CEO Vinay Dube resigns with immediate effect

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Sherpa climbs Mount Everest for record 23rd time

May 15, 2019

Kami Rita Sherpa, a native of Thame village located in the shadow of Mount Everest, reached the 8,850-metre (29,035-feet) summit via the Southeast Ridge route, accompanied by another sherpa.

Jet Airways CEO Vinay Dube resigns with immediate effect

May 14, 2019

An Indian American, Dube's appointment was approved by the airlines' board of directors on May 30, 2017. Dubey has served in various roles at Delta Airlines, Sabre Inc and American Airlines in the US, Europe and Asia.

Pidilite Industries expects double-digit volume growth in FY20

May 15, 2019

Pidilite Industries Ltd on Wednesday said it expects double-digit volume growth for FY20 after it reported a big disappointment in terms of domestic volume growth.

Pakistan's airspace to remain shut for Indian flights till May 30

May 15, 2019

Pakistan on Wednesday decided not to lift its airspace ban for Indian flights till May 30, as Islamabad is awaiting the outcome of the Lok Sabha polls in India.